Abstract
Werner's syndrome is an autosomal recessive disorder resulting in premature aging. Most patients die in their fifth decade from malignancies or heart disease. The gene for Werner's syndrome (WRN) encodes a recQ helicase. Cells from patients with Werner's syndrome have increased sensitivity to DNA-damaging drugs in vitro. Here we present a patient with Werner's syndrome who developed severe chemotherapy-induced toxicity during treatment for acute myelogenous leukemia. We propose that lack of WRN resulted in increased sensitivity of the patient's cells to the toxicity of chemotherapy.
Publication types
-
Case Reports
-
Clinical Trial
-
Clinical Trial, Phase II
-
Review
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Cytarabine / administration & dosage
-
DNA Helicases / genetics
-
Etoposide / administration & dosage
-
Exodeoxyribonucleases
-
Humans
-
Leukemia, Myeloid, Acute / complications
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / enzymology
-
Male
-
Mitoxantrone / administration & dosage
-
RecQ Helicases
-
Werner Syndrome / complications
-
Werner Syndrome / drug therapy*
-
Werner Syndrome / enzymology
-
Werner Syndrome Helicase
Substances
-
Cytarabine
-
Etoposide
-
Mitoxantrone
-
Exodeoxyribonucleases
-
DNA Helicases
-
RecQ Helicases
-
WRN protein, human
-
Werner Syndrome Helicase